Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
Part of paid clinical trials in Fort Myers, Florida.
- Sponsor
- SCRI Development Innovations, LLC
- Study ID
- NCT00193479
- Phase
- PHASE2
- Status
- Completed
Conditions
- Non-Hodgkins Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cyclophosphamide — DRUGCyclophosphamide
- Mitoxantrone — DRUGMitoxantrone
- Vincristine — DRUGVincristine
- Prednisone — DRUGPrednisone
- Rituximab — DRUGRituximab
Study Details
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer programs, and will certainly be better tolerated by this patient group. The addition of maintenance therapy may result in substantial prolongation of remission duration.
Key Dates
- Start date
- Apr 30, 2003
- Status verified
- Feb 2022
- Primary completion
- Jul 31, 2008
- Completion
- Feb 28, 2010
Study Design
- Enrollment
- 51 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cyclophosphamide/Vincristine/Rituximab +/- MitoxantroneAll patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.
Primary Outcome Measure
Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment [ Time Frame: 18 Months ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | - |
| Tennessee Oncology | Nashville | Tennessee | 37203 | - |
Find similar trials in Fort Myers, FL
Related Studies
- Biology Studies of Hematologic CancersEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLPHASE2 · Recruiting · Ascentage Pharma Group Inc. · Houston, Texas
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Springdale, Arkansas